
    
      It consists of a study of a prospective cohort in 36 centers, for 3 years, from April 1st
      2008. The data of all patients who received rFVIIa in traumatic situation were collected. The
      investigators colligated clinical and biological parameters; have been analyzed treatment
      received during initial care, in intensive care before and after they received rFVIIa, length
      of stay in ICU, secondary effects, complications and patients outcome.

      ISS and TRISS score were calculated to predict mortality.
    
  